Canine lymphoma, as the most common hematopoietic malignancy, encompasses a group of heterogeneous diseases and even within the T-cell immunophenotype, differences in clinical presentation and responses to treatment exist. The aim of this retrospective study was to determine outcomes and prognostic factors of 107 dogs with multicentric non-indolent T-cell lymphoma receiving lomustine based (70%) and non-lomustine based (30%) treatment. The majority were Labradors, Boxers, mixed-breed dogs and Dogue de Bordeaux. Eighty-six percent were substage b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement and 12% had other extra-nodal sites of disease. The overall response rate to induction therapy was 80%; dogs receiving procarbazine in the induction protocol (P = .042), dogs with neutrophil concentration below 8.7x10e9/L (P = 0.006) and mitotic rate below 10 per 5 hpf (P = 0.013), had greater response rates. Median progression-free survival (PFS) for the first remission was 105 days; lack of expression of CD3 on flow cytometry (P < 0.0001) and pretreatment with steroid (P = 0.012) were significantly associated with shorter PFS. Median overall survival (OST) was 136 days; co-expression of CD79a (P = 0.002), lack of CD3 expression on flow cytometry, presence of anemia (P = 0.007) and monocytopenia (P = 0.002) were predictive of shorter OST. Multicentric non-indolent T-cell lymphoma in dogs is an aggressive cancer with new possible prognostic factors. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
Disturbance of oxidative stress parameters in treatment-resistant bipolar disorder and their association with electroconvulsive therapy response.
January 24, 2020
July 13, 2020
Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India.
June 22, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.